Sudarshan Pharma shares presentation on proposed USFDA plant acquisition

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹36.00

prior close

₹36.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.2% vs market

Specialty Chemicals peers, median of 94sector-0.1%-0.0% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and in line with its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.1-0.2-0.1-0.0

Next day

-1.1+0.2-1.3-1.1+0.0

+3.8+0.6+3.3-0.9+4.7

+2.8-0.0+2.8-1.2+4.0

+6.3+0.5+5.7-1.3+7.5

+6.1+0.8+5.3-1.0+7.1

+6.4+0.6+5.8-1.0+7.5

15d

+9.7+1.3+8.4+0.6+9.0

+8.3-1.4+9.7-2.0+10.3

+1.7-0.6+2.2-0.9+2.5

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudarshan Pharma filed an updated presentation on its proposed acquisition of a USFDA-approved API manufacturing plant near Visakhapatnam. The 14-acre facility has 4 production blocks with 584 KL total capacity, 200 employees, and approvals from USFDA (2024), WHO Geneva (2024), and ANVISA (2025). It makes APIs and intermediates for antiretrovirals, antifungals, and other drugs. Major customers include Laurus Labs, Cipla, Dr. Reddy's, and Mylan.

Likely market impact

Positive: brings a USFDA-approved API plant with reputed pharma clients. Watch for deal completion and valuation.